Infant Bacterial Therapeutics AB (publ), (IBT) Delårsrapport 1 januari – 30 september 2021
29 oct. 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
VD kommenterar Som bekant genomför IBT en stor fas III-studie (“The Connection Study”) vilket är den sista studien i vårt kliniska utvecklingsprogram med läkemedelskandidaten IBP-9414, som...
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021
29 oct. 2021 02h00 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ), Interim report January 1-September 30, 2021 Message from the CEO As is well known, IBT is conducting a large phase III study ("The Connection Study"), the...
IBT har uppnått ytterligare en milstolpe i sin fas III studie.
30 sept. 2021 13h00 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics (IBT) kan idag meddela att företaget nu har uppnått ytterligare en viktig milstolpe genom att ha rekryterat 600 barn i den pågående kliniska fas III-studien av IBP-9414....
Next recruitment milestone reached in IBT’s Phase III Study.
30 sept. 2021 13h00 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics (IBT) announces that the company has reached the next important milestone after recruiting 600 premature infants in the ongoing Clinical Phase III study of IBP-9414....
Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits.
22 sept. 2021 16h30 HE
|
Infant Bacterial Therapeutics AB
Efter säkerhetsgranskning har rekryteringen av de minsta barnen i the Connection study återupptagits. Efter att säkerhetsgranskningen som utförts av Data Monitoring Committee (DMC) har slutförts kan...
After safety review The Connection study is now again open to recruit the smallest infants.
22 sept. 2021 16h30 HE
|
Infant Bacterial Therapeutics AB
After safety review The Connection study is now again open to recruit the smallest infants. Following the completion of the DMC (Data Monitoring Committee) safety review, IBT is pleased to announce...
Infant Bacterial Therapeutics tillkännager idag att ett nytt patent har godkänts i Mexiko.
10 sept. 2021 06h30 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics tillkännager idag att ett nytt patent har godkänts i Mexiko. Infant Bacterial Therapeutics AB (IBT) meddelar idag att Patentverket i Mexiko beslutat utfärda ett...
Infant Bacterial Therapeutics today announces that a new patent is granted in Mexico
10 sept. 2021 06h30 HE
|
Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics today announces that a new patent is granted in Mexico Infant Bacterial Therapeutics AB today announces that the Mexican Patent Office has granted a patent entitled: A...
Rekryteringen av de minsta barnen i the Connection study pausad
25 août 2021 06h50 HE
|
Infant Bacterial Therapeutics AB
IBT påbörjade rekrytering av spädbarn till Strata A (vikt 500g-749g) i The Connection Study den 29 april 2021. Idag har 68 spädbarn rekryterats till gruppen. I enlighet med studieprotokollet och...
Recruitment of the smallest infants in the Connection study paused
25 août 2021 06h50 HE
|
Infant Bacterial Therapeutics AB
IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol...